Therapeutic efficacy of ABN401, a highly potent and selective MET inhibitor, based on diagnostic biomarker test in MET-addicted cancer

7Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

The receptor tyrosine kinase c-MET regulates processes essential for tissue remodeling and mammalian development. The dysregulation of c-MET signaling plays a role in tumorigenesis. The aberrant activation of c-MET, such as that caused by gene amplification or mutations, is associated with many cancers. c-MET is therefore an attractive therapeutic target, and inhibitors are being tested in clinical trials. However, inappropriate patient selection criteria, such as low amplification or expression level cut-off values, have led to the failure of clinical trials. To include patients who respond to MET inhibitors, the selection criteria must include MET oncogenic addiction. Here, the efficacy of ABN401, a MET inhibitor, was investigated using histopathologic and genetic analyses in MET-addicted cancer cell lines and xenograft models. ABN401 was highly selective for 571 kinases, and it inhibited c-MET activity and its downstream signaling pathway. We performed pharmacokinetic profiling of ABN401 and defined the dose and treatment duration of ABN401 required to inhibit c-MET phosphorylation in xenograft models. The results show that the efficacy of ABN401 is associated with MET status and they highlight the importance of determining the cut-off values. The results suggest that clinical trials need to establish the characteristics of each sample and their correlations with the efficacy of MET inhibitors.

References Powered by Scopus

UCSF Chimera - A visualization system for exploratory research and analysis

35314Citations
N/AReaders
Get full text

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

23781Citations
N/AReaders
Get full text

A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules

12095Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Behind the Scenes of Anthocyanins—From the Health Benefits to Potential Applications in Food, Pharmaceutical and Cosmetic Fields

51Citations
N/AReaders
Get full text

Computational study on potential novel anti-ebola virus protein vp35 natural compounds

13Citations
N/AReaders
Get full text

Relevance of Circulating Tumor Cells as Predictive Markers for Cancer Incidence and Relapse

11Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kim, J., Park, K. E., Jeong, Y. S., Kim, Y. M., Park, H., Nam, J. H., … Shin, Y. K. (2020). Therapeutic efficacy of ABN401, a highly potent and selective MET inhibitor, based on diagnostic biomarker test in MET-addicted cancer. Cancers, 12(6), 1–23. https://doi.org/10.3390/cancers12061575

Readers over time

‘20‘21‘23‘24036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

50%

Researcher 4

50%

Readers' Discipline

Tooltip

Medicine and Dentistry 7

54%

Biochemistry, Genetics and Molecular Bi... 4

31%

Pharmacology, Toxicology and Pharmaceut... 1

8%

Chemistry 1

8%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 1

Save time finding and organizing research with Mendeley

Sign up for free
0